The num­bers are in on Te­va CEO Kåre Schultz’s 2021 pay pack­age — and while his comp was a bit low­er than last year, it still rang high­er than some of Eu­rope’s top-paid phar­ma ex­ecs.

Schultz took home near­ly $14.7 mil­lion last year, up from about $15.7 mil­lion the year pri­or. About $2 mil­lion of that was con­sid­ered base salary, ac­cord­ing to Te­va’s com­pen­sa­tion re­port. The 60-year-old chief ex­ec­u­tive has been at the helm since 2017.

That pay cut could be due to the fact that rev­enues were down 5% last year com­pared to 2020, which the com­pa­ny at­trib­uted in part to gener­ic com­pe­ti­tion to its mul­ti­ple scle­ro­sis drug Co­pax­one.

Best known as a ma­jor mak­er of gener­ics, Te­va has been steadi­ly boot­ing up R&D for brand­ed drugs as part of a promised turn­around. Back in Au­gust, it re­cruit­ed Mod­er­na vet­er­an Tal Zaks to its board. The com­pa­ny’s Hunt­ing­ton’s dis­ease treat­ment Auste­do and mi­graine med Ajovy will be a big part of those ef­forts, Schultz said, both of which saw in­creas­es in sales last year part­ly mak­ing up for Co­pax­one’s low­er num­bers.

“Look­ing for­ward to 2022, we ex­pect to see con­tin­ued growth of our key prod­ucts AUSTE­DO and AJOVY, as well as to con­tin­ue to ad­vance our core busi­ness through the launch of high qual­i­ty gener­ic med­i­cines around the world,” Schultz said in a state­ment re­gard­ing the com­pa­ny’s Q4 re­sults.

Te­va al­so not­ed the im­pact of the on­go­ing Covid-19 pan­dem­ic.

How­ev­er, Schultz still took home a sig­nif­i­cant­ly high­er amount than some of Eu­rope’s high­est-earn­ing phar­ma chiefs, in­clud­ing Roche CEO Sev­erin Schwan who raked in 11.5 mil­lion CHF ($12.4 mil­lion) last year, and No­var­tis head Vas Narasimhan, who claimed 11.2 mil­lion CHF ($12 mil­lion).

Those num­bers pale in com­par­i­son to what some of the US’ top-paid phar­ma ex­ecs see on a year­ly ba­sis, in­clud­ing J&J’s Alex Gorsky, who brought home right around $26.7 mil­lion last year, a $2.8 mil­lion drop com­pared to the year be­fore. Eli Lil­ly’s Dave Ricks amassed $23.7 mil­lion in 2020, while Gio­van­ni Caforio at Bris­tol My­ers Squibb claimed $20 mil­lion for the same stretch.

Digital therapeutics company Better Therapeutics announced on Thursday that it’s cutting 35% of its staff as it awaits FDA clearance for its first product.

The company, which launched eight years ago, is one of a growing group of companies seeking a digital alternative to traditional medicine. The space saw a record $7.5 billion in investments in 2021, according to Chris Dokomajilar at DealForma, with uses spanning ADHD, PTSD and other indications. However, private insurers have been slow to hop on board.

A California judge will allow a plaintiff in a state court case to introduce expert testimony connecting a potential carcinogen in former blockbuster medicine Zantac to cancer.

The order was handed down on Thursday from state judge Evelio Grillo, who is now allowing both parties to introduce expert testimony in an upcoming trial after what’s known as a Sargon hearing, where a judge determines the admissibility of expert witnesses and expert opinions.